UK launch for cholesterol-lowering PCSK9 inhibitor
![Evolocumab is the first treatment to act by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), pictured, an enzyme that reduces the liver’s ability to clear LDL cholesterol (‘bad’ cholesterol) from the blood](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20100%2056%22%3E%3C/svg%3E)
An injectable treatment has been launched for people who struggle to control their cholesterol levels through established diet and drug regimes, including patients with the genetic lipid disorder familial hypercholesterolaemia.…